You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

415 Results
Document
Jan 2021
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    ripretinib - For adult patients with advanced gastrointestinal stromal tumours (GIST) who have progression on or intolerance to imatinib, sunitinib and regorafenib
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
ripretinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2023
Cancer facts
Mar 2021
Document
Apr 2021
Document
May 2021
Document
Jun 2021
Document
Oct 2021
Document
Oct 2021
Cancer facts
Nov 2021
Guidelines and Advice
May 2021

Pages